Elite Pharmaceuticals Inc (ELTP)
0.6168
0.00 (0.00%)
USD |
OTCM |
Nov 22, 15:59
Elite Pharmaceuticals Revenue (Quarterly): 18.88M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 18.88M |
| June 30, 2024 | 18.80M |
| March 31, 2024 | 17.95M |
| December 31, 2023 | 15.54M |
| September 30, 2023 | 14.16M |
| June 30, 2023 | 8.980M |
| March 31, 2023 | 8.642M |
| December 31, 2022 | 9.250M |
| September 30, 2022 | 8.586M |
| June 30, 2022 | 7.673M |
| March 31, 2022 | 7.672M |
| December 31, 2021 | 8.975M |
| September 30, 2021 | 8.558M |
| June 30, 2021 | 7.057M |
| March 31, 2021 | 4.396M |
| December 31, 2020 | 6.047M |
| September 30, 2020 | 7.400M |
| June 30, 2020 | 7.539M |
| March 31, 2020 | 4.945M |
| December 31, 2019 | 5.055M |
| September 30, 2019 | 4.635M |
| June 30, 2019 | 3.359M |
| March 31, 2019 | 1.344M |
| December 31, 2018 | 2.694M |
| September 30, 2018 | 1.363M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.168M |
| March 31, 2018 | 1.597M |
| December 31, 2017 | 2.536M |
| September 30, 2017 | 1.624M |
| June 30, 2017 | 1.703M |
| March 31, 2017 | 1.350M |
| December 31, 2016 | 2.331M |
| September 30, 2016 | 2.686M |
| June 30, 2016 | 3.271M |
| March 31, 2016 | 5.195M |
| December 31, 2015 | 2.194M |
| September 30, 2015 | 2.946M |
| June 30, 2015 | 2.163M |
| March 31, 2015 | 1.234M |
| December 31, 2014 | 1.363M |
| September 30, 2014 | 1.256M |
| June 30, 2014 | 1.162M |
| March 31, 2014 | 1.028M |
| December 31, 2013 | 1.693M |
| September 30, 2013 | 1.159M |
| June 30, 2013 | 0.7217M |
| March 31, 2013 | 1.523M |
| December 31, 2012 | 0.6677M |
| September 30, 2012 | 0.6345M |
| June 30, 2012 | 0.5786M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
4.396M
Minimum
Mar 2021
18.88M
Maximum
Sep 2024
9.805M
Average
8.572M
Median
Revenue (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 745.74M |
| BioCardia Inc | -- |
| Zevra Therapeutics Inc | 3.695M |
| Verrica Pharmaceuticals Inc | -1.781M |
| Terns Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -11.04M |
| Total Expenses (Quarterly) | 15.40M |
| EPS Diluted (Quarterly) | -0.01 |
| Enterprise Value | 657.76M |
| Gross Profit Margin (Quarterly) | 43.42% |
| Profit Margin (Quarterly) | -58.45% |
| Earnings Yield | -1.42% |
| Operating Earnings Yield | 2.25% |
| Normalized Earnings Yield | 0.5857 |